Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors

Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors
Silexion Therapeutics Corp (NASDAQ:SLXN) announces breakthrough preclinical results for SIL204, a next-gen RNAi therapy showing potent anti-tumor effects in KRAS-driven cancers.